What is antibody humanization?

Antibody humanization is a process used to modify non-human antibodies, typically from murine sources, to resemble human antibodies more closely. This is achieved by grafting the complementarity-determining regions (CDRs) of a non-human antibody into a human antibody framework, minimizing the introduction of non-human elements that could elicit an immune response.

How does antibody humanization contribute to de-immunization?

By converting a non-human antibody into a more human-like form, antibody humanization reduces the immunogenicity of therapeutic antibodies. This modification decreases the likelihood of the immune system recognizing and attacking the antibody, thus enhancing the safety and efficacy of treatments for a wide range of diseases.

What are the key steps involved in antibody humanization?

The process begins with the identification of the CDRs in the original, non-human antibody that are responsible for antigen binding. These regions are then grafted onto a human antibody scaffold. The resulting construct is often further modified to improve its stability, binding affinity, and to reduce potential immunogenicity.

How are humanized antibodies tested for de-immunization effectiveness?

Humanized antibodies are evaluated through a combination of in vitro and in vivo assays to assess their immunogenic potential. These include binding assays, immunoassays, and potentially clinical trials to observe any adverse immune reactions in humans.

What advancements are improving antibody humanization techniques?

Advances in bioinformatics and computational biology are enabling more accurate predictions of immunogenic epitopes and better designs for antibody frameworks. Improvements in screening technologies also allow for more efficient selection of optimal antibody candidates post-humanization.

Can all types of antibodies be humanized?

While most antibodies can be humanized, the success of this process can vary based on the structure and function of the original antibody. Some antibodies may require extensive engineering beyond CDR grafting to achieve desired therapeutic properties and minimal immunogenicity.

What impact does antibody humanization have on the cost of therapy?

Initially, the development and testing of humanized antibodies can be costly due to the complex engineering and extensive validation required. However, the potential reduction in adverse immune reactions and the broader applicability of these therapies can lead to significant long-term cost savings in clinical settings.

RDIT^® Antibody Humanization Service

Introduction RDIT^® Antibody Humanization FAQ Resources

The humanized antibody mainly refers to antibody that is re-expressed by a mouse monoclonal antibody via gene cloning and DNA recombination technology. Most of the amino acid sequences are substituted by human sequences, but the affinity and specificity of murine monoclonal antibodies are substantially retained. Simultaneously, the heterologous properties are reduced, which is beneficial to the human body. Recent research has also revealed that antibody humanization should be a powerful tool for the de-immunogenicity of therapeutic antibodies. Creative Biolabs owns a high-level technical team and instruments to provide antibody humanization services to reduce the immunogenicity of your targets of interest.

Introduction of Antibody Humanization

A humanized antibody means that the constant region portion of the antibody (i.e., the CH and CL regions) or the antibody are all encoded by the human antibody gene. Humanized antibodies can greatly reduce the immune side effects of heterologous antibodies on the human body. A wide variety of humanized antibodies, including chimeric antibodies, modified antibodies, surface remodeling of antibodies, as well as fully humanized antibodies have been developed for disease therapy. Meanwhile, pilot studies have indicated that antibody humanization plays an important role in reducing the immunogenicity of potential antibodies in disease treatment.

Fig.1 Antibody engineering for humanization. (Kim, 2005)

RDIT^® Antibody Humanization Services

As a professional immunogenicity analysis supplier for therapeutic antibody discovery, Creative Biolabs has developed a novel Rapid De-immunization Technology^® (RDIT^®) antibody humanization platform to improve the safety and efficacy of candidate antibodies in pre-clinical studies. Currently, we offer a number of antibody humanization services to help the de-immunogenicity of screened targets. Unlike other platforms, the specificity determining residues (SDRs) of the antibody will be engineered into the human framework. In general, the three-dimensional structures, mutation sites of SDRs will be defined by our RDIT^® in silico analysis assays. After that, a series of functional assays will be further used to assess the safety, reactivity of the humanized antibody to the patient serum. In addition, we also provide a phage display-based strategy to help the de-immunogenicity of antibodies by using human sequences from phage-displayed antibody libraries. Recent studies conducted by our labs have suggested that RDIT^® antibody humanization platform can provide a fast and accurate route for antibody humanization. Basing on our services, the humanized antibody can present a high affinity, specificity, and much fewer immunogenicity properties in the production or long-term treatment process.

Creative Biolabs provides high quality humanized antibody recombination services and technical support to reduce the immunogenicity of the drug. If you are interested in humanized antibody, please contact us for more details.

Other optional RDIT^® antibody drug de-immunization services:

Reference

Kim, S.J.; et al. Antibody Engineering for the Development of Therapeutic Antibodies. Molecules and Cells. 2005, 20(1): 17-29.

FAQ

What is antibody humanization?
Antibody humanization is a process used to modify non-human antibodies, typically from murine sources, to resemble human antibodies more closely. This is achieved by grafting the complementarity-determining regions (CDRs) of a non-human antibody into a human antibody framework, minimizing the introduction of non-human elements that could elicit an immune response.
How does antibody humanization contribute to de-immunization?
By converting a non-human antibody into a more human-like form, antibody humanization reduces the immunogenicity of therapeutic antibodies. This modification decreases the likelihood of the immune system recognizing and attacking the antibody, thus enhancing the safety and efficacy of treatments for a wide range of diseases.
What are the key steps involved in antibody humanization?
The process begins with the identification of the CDRs in the original, non-human antibody that are responsible for antigen binding. These regions are then grafted onto a human antibody scaffold. The resulting construct is often further modified to improve its stability, binding affinity, and to reduce potential immunogenicity.
How are humanized antibodies tested for de-immunization effectiveness?
Humanized antibodies are evaluated through a combination of in vitro and in vivo assays to assess their immunogenic potential. These include binding assays, immunoassays, and potentially clinical trials to observe any adverse immune reactions in humans.
What advancements are improving antibody humanization techniques?
Advances in bioinformatics and computational biology are enabling more accurate predictions of immunogenic epitopes and better designs for antibody frameworks. Improvements in screening technologies also allow for more efficient selection of optimal antibody candidates post-humanization.
Can all types of antibodies be humanized?
While most antibodies can be humanized, the success of this process can vary based on the structure and function of the original antibody. Some antibodies may require extensive engineering beyond CDR grafting to achieve desired therapeutic properties and minimal immunogenicity.
What impact does antibody humanization have on the cost of therapy?
Initially, the development and testing of humanized antibodies can be costly due to the complex engineering and extensive validation required. However, the potential reduction in adverse immune reactions and the broader applicability of these therapies can lead to significant long-term cost savings in clinical settings.